申请人:Endo Laboratories, Inc.
公开号:US04183936A1
公开(公告)日:1980-01-15
##STR1## where X is O, S, S.fwdarw.O, or SO.sub.2 ; n is 0 or 1; m is 0 or 1; the R's are the same or different and are H or CH.sub.3, and one of them can be C.sub.2 -C.sub.9 alkyl, phenyl, C.sub.7 -C.sub.10 phenylalkyl, furyl, thienyl, pyridyl or substituted phenyl or phenylalkyl; when X is S, and m is 0, one R in the group --RCR-- can be OCH.sub.3 ; when X is S and m is 1, the R in the group (CHR).sub.m can be OCH.sub.3 ; and R.sup.1 is H, C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.5 alkenyl, C.sub.3 -C.sub.5 alkynyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.2 -C.sub.4 alkoxycarbonyl, trifluoroacetyl, or substituted C.sub.1 -C.sub.4 alkyl where the substituent is C.sub.3 -C.sub.6 cycloalkyl, phenyl or substituted phenyl; and their pharmaceutically suitable salts. The compounds are useful as sedatives; some of them also exhibit antidepressant, antihypertensive and antibacterial activity. The compounds are prepared by cyclizing compounds of formula II ##STR2## wherein R.sup.2 is R.sup.1 or acyl. The latter compounds are prepared by reacting 4-piperidones with compounds of formula III in the presence of a reducing agent ##STR3## or with compounds of formula VI ##STR4##
该化合物具有以下结构式:##STR1##其中X为O、S、S.fwdarw.O或SO.sub.2;n为0或1;m为0或1;R的取值相同或不同,为H或CH.sub.3,其中一个可以是C.sub.2-C.sub.9烷基、苯基、C.sub.7-C.sub.10苯基烷基、呋喃基、噻吩基、吡啶基或取代的苯基或苯基烷基;当X为S且m为0时,群组--RCR--中的一个R可以是OCH.sub.3;当X为S且m为1时,群组(CHR).sub.m中的R可以是OCH.sub.3;R.sup.1为H、C.sub.1-C.sub.4烷基、C.sub.3-C.sub.5烯基、C.sub.3-C.sub.5炔基、C.sub.3-C.sub.6环烷基、C.sub.2-C.sub.4烷氧羰基、三氟乙酰基或取代的C.sub.1-C.sub.4烷基,其中取代基为C.sub.3-C.sub.6环烷基、苯基或取代的苯基;以及其药学上合适的盐。这些化合物有镇静作用;其中一些还具有抗抑郁、降压和抗菌活性。这些化合物通过环化式II的化合物制备而成:##STR2##其中R.sup.2为R.sup.1或酰基。后者的化合物通过在还原剂的存在下将4-哌啶酮与式III的化合物反应而制备得到:##STR3##或与式VI的化合物反应而制备得到:##STR4##